Abstract
Aim. To identify the major clinical manifestations and assess current capabilities of laboratory and instrumental dignostic methods for neuroendocrine tumors of the pancreas and gastrointestinal to justify the choice of surgical treatment. Materials and Methods. Results of treatment of 202 patients with neuroendocrine tumors are presented. There were 124 patients with pancreatic tumors and 78 patients with tumors of various parts of gastrointestinal tract. Diagnosis of neuroendocrine tumors included laboratory confirmation of clinical neuroendocrine syndrome and topical diagnosis. Surgical treatment was applied in 199 patients. Long-term results were studied based on regression of clinical and laboratory manifestations of neuroendocrine pathology and 5-year survival. Results. Clinical manifestations of gastrointestinal neuroendocrine tumors are nonspecific in 90% of patients that extends the terms of diagnosis. The sensitivity of laboratory methods for diagnosis of pancreatic neuroendocrine tumors was 96%, for gstrointestinal tract – 92%. The most accessible methods of topical diagnosis of pancreatic neuroendocrine tumors are CT and endoscopic ultrasound with sensitivity 75% and 91%, respectively. It is advisable to complement diagnosis by intraoperative sonography. Sensitivity of endoscopic methods of investigation (fibrogastroduodenoscopy, fibrocolonoscopy) in the diagnosis of gastrointestinal neuroendocrine tumors is 96.2%. PET with 18-fluorodeoxyglucose is an optional method of detecting the tumoral process generalization. Surgical treatment eliminated the symptoms of neuroendocrine syndrome and provided overall 5-year survival of 69.3 ± 4.7% in radically operated patients with pancreatic neuroendocrine tumors and 63.0 ± 5.2% in patients with gastrointestinal neuroendocrine tumors. Conclusion. Laboratory and instrumental methods confirm clinical neuroendocrine syndrome and localized tumors in pancreas and different parts of gastrointestinal tract. Surgical treatment can eliminate symptoms of neuroendocrine syndrome, improve 5-year survival and quality of life.
Highlights
Clinical manifestations of gastrointestinal neuroendocrine tumors are nonspecific in 90% of patients that extends the terms of diagnosis
Surgical treatment eliminated the symptoms of neuroendocrine syndrome and provided overall 5-year survival of 69.3 ± 4.7% in radically operated patients with pancreatic neuroendocrine tumors and 63.0 ± 5.2% in patients with gastrointestinal neuroendocrine tumors
Вместе с тем результаты дооперационного морфологического исследования Нейроэндокринные опухоли (НЭО) поджелудочной железы (ПЖ) позволяют определить степень злокачественности опухоли не более чем в 30% наблюдений, а основными критериями, определяющими ее злокачественный потенциал, являются инструментальные признаки инфильтративного роста, регионарного и отдаленного метастазирования
Summary
Проявления нейроэндокринных опухолей желудочно-кишечного тракта носят неспецифический характер у 90% больных, что удлиняет сроки их диагностики. Чувствительность лабораторных методов диагностики нейроэндокринных опухолей поджелудочной железы составила 96%, желудочно-кишечного тракта – 92%. Хирургическое лечение позволило устранить проявления нейроэндокринного синдрома и достигнуть общей пятилетней выживаемости у 69,3 ± 4,7% радикально оперированных больных нейроэндокринными опухолями поджелудочной железы и у 63,0 ± 5,2% больных нейроэндокринными опухолями желудочно-кишечного тракта. Clinical manifestations of gastrointestinal neuroendocrine tumors are nonspecific in 90% of patients that extends the terms of diagnosis. The sensitivity of laboratory methods for diagnosis of pancreatic neuroendocrine tumors was 96%, for gstrointestinal tract – 92%. The most accessible methods of topical diagnosis of pancreatic neuroendocrine tumors are CT and endoscopic ultrasound with sensitivity 75% and 91%, respectively. Sensitivity of endoscopic methods of investigation (fibrogastroduodenoscopy, fibrocolonoscopy) in the diagnosis of gastrointestinal neuroendocrine tumors is 96.2%. Surgical treatment eliminated the symptoms of neuroendocrine syndrome and provided overall 5-year survival of 69.3 ± 4.7% in radically operated patients with pancreatic neuroendocrine tumors and 63.0 ± 5.2% in patients with gastrointestinal neuroendocrine tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
